Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Amicus Therapeutics (FOLD) Tops Q1 EPS by 5c, Misses on Revenue
May 1, 2025 7:06 AM EDT(Updated - May 1, 2025 10:00 AM EDT)
Amicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of $0.03, $0.05 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $125.25 million versus the consensus estimate of $136.65 million.
For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.
... More